You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 1, 2011

Ensuring Smooth Registration of Pharmaceutical Products

Subscribe to Updates
PReMA Life

The registration of a pharmaceutical product with the Food and Drug Administration (FDA) can be extremely time consuming, even for straightforward cases. In order to avoid any delays, it is important that the product dossier be meticulously prepared prior to submitting all relevant documents to the FDA, especially the quality part of the documentation.

We discussed the issue with the Department of Medical Science (DMSc) quality part examiners to clarify the process, provide key pointers to avoid common mistakes, and obtain their views and opinions on some of the most common difficulties typically encountered when reviewing a dossier.

Regulatory Changes

Due to changes in requirements from ASEAN Harmonization of Standards and Technical Requirements for Pharmaceutical Products, applicants should carefully follow the developments of the regulations for product registration to ensure that there are no missing documents and that they have not overlooked any newly introduced requirements.

Method Verification and Method Validation

New applications will likely have to be filed for all non‐ASEAN compliant pharmaceutical products, or amendments will have to be made to the quality part of such products. This includes the Method Verification and Analytical Method Validation aspects.

The Method Verification is the confirmation procedure by performing the analytical method in complying with the compendia method for the users of such methods. The manufacturers who use the United States Pharmacopoeia analytical method have to demonstrate their competence in successfully operating the method by providing the documents to verify the suitability of such methods.

The Analytical Method Validation is a confirmatory process of performing several tests which are designed to verify that an analytical test system is suitable for its intended purpose, and is capable of providing useful and valid analytical data. Thus, Analytical Method Validation is required for a newly developed method, non compendia, such as an in‐house method (i.e., a method that was developed by the manufacturer itself), and modified compendia procedures etc.

Applicants should also ensure that references from pharmacopoeia are not obsolete when submitting documents for the analytical part of the assay.

Zone IVb Stability Data

All previously registered pharmaceutical products have until 2012 to amend the stability data provided in their respective dossiers. Zone IVb stability data of 30 C +-2, 75 +-5% RH is now required. This includes long term and real time Zone IVb Stability data, which is a new requirement

Carefully prepared data that meets the FDA guidelines will hopefully avoid any unnecessary delays and ensure the earliest and smoothest product launch.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

June 9, 2021
The latest updates to Practical Law’s Life Sciences Global Guide feature two revised sections from Tilleke & Gibbins attorneys in the firm’s Jakarta office—“Medicinal Product Regulation and Product Liability in Indonesia,” and “Pharmaceutical IP and Competition Law in Indonesia.” “Medicinal Product Regulation and Product Liability in Indonesia” covers a range of regulatory issues related to the marketing and selling of pharmaceutical products, including the following: Regulatory overview, including relevant laws and authorities, scope, definitions, and general procedures for pharmaceuticals, biologicals, and medical devices and health care IT Pricing, government funding, and reimbursement: Structure of Indonesia’s health care system, price regulation, and reimbursement Clinical trials Manufacturing and distribution Marketing: Authorization for marketing medicinal products, parallel imports and cross-border trade in medicines Restrictions on dealings with health care professionals Selling restrictions Advertising and promotion Data privacy Packaging, labeling, and tracking Product safety, quality, and liability Local establishment, representation, and residency requirements Reform The full “Medicinal Product Regulation and Product Liability in Indonesia” section can be accessed on the Practical Law website. “Pharmaceutical IP and Competition Law in Indonesia” first goes over the country’s legal and regulatory environment for patents and trademarks in relation to pharmaceutical business operations in the jurisdiction. The section then turns to competition law issues, with the Q&A format focusing on how the country’s competition laws and regulations affect the pharmaceutical sector. Readers are also given information on how to properly comply with Indonesian competition law, including in the licensing of medicines and pharmaceutical technology. The full “Pharmaceutical Intellectual Property and Competition Law in Indonesia” section can be found on the Practical Law website. Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas.
Read More
May 27, 2021
The new regulations for using Indonesia’s SIAPIK system have the potential to affect companies’ advertising plans and help maintain the relevance and effectiveness of Indonesia’s drug advertising regulatory environment
Read More
May 27, 2021
On March 1, 2021, the government of Vietnam promulgated Decree No. 14/2021/ND-CP on Penalties for Administrative Violations Involving Animal Husbandry (Decree 14). The new decree took effect on April 20 and, among other contents, repeals the regulations on animal feed found in Decree No. 64/2018/ND-CP dated May 7, 2018. In the field of animal feed, notable penalties of Decree 14 include the following: Penalty forms and levels For each administrative violation, the violator will be imposed a monetary penalty, which is the main penalty form. For the same violation, the monetary penalty level applied to an organization is double the amount applied to an individual. In addition, based on the nature and extent of the violation, additional penalties may be imposed on the violators, including confiscation of violating items, and confiscating Certificates of Eligibility to manufacture animal feeds. Violations of regulations on declaring product information A fine of up to VND 3 million (USD 130) will be imposed for the act of changing information on product labels that has been published on the Portal of the Ministry of Agriculture and Rural Development (MARD) without conducting the notification procedure to inform the MARD of such change. A fine of up to VND 7 million (USD 300) will be imposed for the act of deliberately falsifying or erasing contents of documents or making false declarations in the applications for animal feed products on the Portal of the MARD. Violation of regulations on quality in importing animal feed A fine of up to VND 25 million (USD 1,080) will be imposed for the act of importing each animal feed having (i) a quantitative content of each quality criterion lower than the minimum level or higher than the maximum level compared with the standards announced or written on the goods label; or (ii)
Read More